Clinical Trials Logo

Acquired Bleeding Disorder clinical trials

View clinical trials related to Acquired Bleeding Disorder.

Filter by:

NCT ID: NCT01561417 Completed - Healthy Clinical Trials

Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects

Start date: April 2006
Phase: Phase 1
Study type: Interventional

This trial is conducted in Europe. The aim of this trial is to demonstrate bio-equivalence between the marketed activated recombinant human factor VII (NovoSeven®) (CP-rFVIIa) and a new formulation stable at 25°C (VII25).

NCT ID: NCT01285089 Completed - Clinical trials for Acquired Bleeding Disorder

Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia

ACQUI-7
Start date: December 2010
Phase: N/A
Study type: Observational

This study is conducted in Europe. The aim of this prospective, observational study are to describe the different clinical practice and detailed haemostatic management of activated recombinant human factor VII (NovoSeven®) in patients with acquired haemophilia in France. The secondary aim is to assess the primary haemostasis disorder associated with the coagulation disorders, if available.

NCT ID: NCT01153997 Completed - Healthy Clinical Trials

Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese Volunteers

Start date: June 2010
Phase: Phase 1
Study type: Interventional

This trial is conducted in Japan. The aim of this trial is to investigate the safety profile of recombinant factor XIII (rFXIII) assessed by the occurrence of adverse events in healthy Japanese subjects. In addition pharmacokinetic parameters will be investigated.

NCT ID: NCT00914589 Completed - Clinical trials for Acquired Bleeding Disorder

Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery

Start date: July 2009
Phase: Phase 2
Study type: Interventional

This trial is conducted in Canada, Asia, Europe and USA. The aim of this clinical trial is to investigate the effect and safety of rFXIII on transfusion needs in patients undergoing heart surgery.

NCT ID: NCT00697320 Completed - Clinical trials for Congenital Bleeding Disorder

Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in Germany

WIRK
Start date: June 2008
Phase: N/A
Study type: Observational

This NON INTERVENTIONAL OBSERVATIONAL STUDY is conducted in Europe. The primary aim is to observe the haemostatic efficacy of NovoSeven® treatment during routine practice in German clinics. The observational study observes patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX, acquired haemophilia, congenital FVII deficiency, or Glanzmann's thrombasthenia who have received at least one dose of NovoSeven® for treatment of a bleeding episode or for the prevention of a bleeding when undergoing surgery or an invasive procedure.

NCT ID: NCT00426803 Completed - Clinical trials for Acquired Bleeding Disorder

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

Start date: August 2002
Phase: Phase 2
Study type: Interventional

This trial is conducted in North America, Europe, Asia and Oceania. The purpose of this study is to evaluate safety and efficacy of Recombinant Factor VIIa in patients with acute intracerebral bleeding.

NCT ID: NCT00266006 Completed - Clinical trials for Acquired Bleeding Disorder

Factor VIIa in Acute Intracerebral Haemorrhage

Start date: January 2006
Phase: Phase 2
Study type: Interventional

This trial is conducted in Japan. The purpose of this trial is to evaluate the safety and preliminary efficacy of Activated Recombinant Factor VII (NN-007) in patients with acute intracerebral haemorrhage.

NCT ID: NCT00154492 Completed - Cirrhosis Clinical Trials

Use of NovoSeven® in Active Variceal Bleeding

Start date: April 2004
Phase: Phase 2
Study type: Interventional

This trial is conducted in Asia and Europe. The trial is planned to investigate the effectiveness and safety of NovoSeven® in patients with advanced cirrhosis and active variceal bleeding.

NCT ID: NCT00127283 Completed - Clinical trials for Acquired Bleeding Disorder

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

FAST
Start date: May 2005
Phase: Phase 3
Study type: Interventional

This trial is conducted in Asia, Europe, Middle East, North America, Oceania, and South America. The purpose of this study is to evaluate the treatment of Recombinant Factor VIIa (eptacog alfa (activated)) in patients with acute intracerebral bleeding. It is expected that more patients will recover without severe permanent disability after acute treatment with Recombinant Factor VIIa by reducing further intracerebral bleeding.

NCT ID: NCT00124293 Completed - Trauma Clinical Trials

Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury

Start date: October 6, 2004
Phase: N/A
Study type: Observational

This study is conducted in North America. The purpose of this study is to evaluate the occurrence and severity of bleeding in brain injury and to identify important safety issues following traumatic brain injury.